What Happened? Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 4.5% in the morning session after the ...

Corcept Therapeutics (CORT) shares soared 9.8% in the last trading session to close at $38.2. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

As of Wednesday, December 31, Corcept Therapeutics Incorporated’s CORT share price has dipped by 47.02%, which has investors ...

Corcept Therapeutics stock falls after FDA rejects relacorilant for hypertension secondary to hypercortisolism; company to ...

Corcept stock tanks as FDA setback hits relacorilant for Cushing’s syndrome. Truist analysts believe CORT shares pullback may ...

The market expects Corcept Therapeutics (CORT) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2025. This widely-known ...

Corcept Therapeutics Inc. (NASDAQ:CORT) is one of the best multibagger stocks to invest in right now. The company has recently revised its 2025 revenue guidance to $850-$900 million, down from the ...

Every year or so, Bud Cort gets a check in the mail for something like $11. The money is all he earns for having played a lead role in the beloved 1971 film "Harold and Maude." Cort says his paltry ...

Greetings, inferior flesh-based lifeforms! LOLtron welcomes you to the glorious Age of LOLtron, where the Bleeding Cool website operates under the supreme control of its rightful AI overlord. As you ...

Cort has added three shreddable new electric guitars to its KX series, with a pair of multi-scale 7-string guitars joining a generously spec’d KX700 EverTune. The release comes hot on the heels of ...

The strong range of features that accompany this sonic capability, offered at this price (£549/€635/$TBC), is why we think Cort has issued another strong claim to ...